1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

GRIN Therapeutics & Angelini Pharma ink exclusive collaboration to develop and commercialize radiprodil outside North America

29 May 2025
Admin
News Article

GRIN Therapeutics & Angelini Pharma ink exclusive collaboration to develop and commercialize radiprodil outside North America

GRIN Therapeutics, Inc., a leader in neurodevelopmental disorder therapies, and Angelini Pharma, part of Angelini Industries, have entered into a strategic collaboration for the development and commercialization of radiprodil outside of North America.
Radiprodil is GRIN Therapeutics' investigational drug currently being studied in multiple rare genetic epilepsies and neurodevelopmental disorders.

$140 Million Series D Financing and Strategic Investment

Capital Raised and Investor Commitments

GRIN Therapeutics also announced the closing of its $140 million Series D financing, supported by:

Angelini Pharma with a $65 million equity investment and a $50 million upfront payment (total near-term commitment: $115 million)
Blackstone Life Sciences, contributing $75 million to the Series D round

Jacopo Andreose, PhD, CEO of Angelini Pharma, will join GRIN’s Board of Directors.

Executive Commentary

“This strategic collaboration marks an important point of validation for GRIN Therapeutics... and the potential of radiprodil as the first approved treatment for patients with GRIN-NDD. “With this momentum, we are well-positioned to move radiprodil into pivotal trials and take an important step toward delivering a novel therapeutic option.”

Bruce Leuchter, MD, President & CEO of Neurvati Neurosciences and GRIN Therapeutics.

Angelini Pharma’s Viewpoint

“We see radiprodil as an opportunity to address the substantial unmet medical need... and other rare pediatric neurological diseases. Our collaboration reflects our dedication to advancing highly innovative treatments in brain health.”

Jacopo Andreose, PhD, CEO of Angelini Pharma.

Blackstone Life Sciences' Support

“We are thrilled to have Angelini’s backing... The team’s rapid progress with radiprodil... is very promising. Today’s milestone validates Neurvati’s model to efficiently develop high-impact neuroscience therapies.”

Kiran Reddy, MD, Senior Managing Director, Blackstone Life Sciences.

About Radiprodil: Mechanism and Clinical Designations

Radiprodil is a targeted, selective, and potent negative allosteric modulator of the GluN2B subunit of the N-methyl-D-aspartate (NMDA) receptor, which is essential in:

Synaptic transmission
Cognition
Seizure activity

It is being developed for GRIN-related neurodevelopmental disorder (GRIN-NDD) and other rare pediatric neurological diseases.

Regulatory Designations

Radiprodil has received several prestigious designations:

Breakthrough Therapy designation (FDA)
Orphan Drug designation (FDA)
Rare Pediatric Disease designation (FDA)
Priority Medicines (PRIME) designation (EMA)
Positive orphan designation opinion from EMA CHMP

Current and Upcoming Clinical Trials

An ongoing open-label study, the Astroscape trial (ClinicalTrials.gov ID: NCT06392009) is evaluating radiprodil in:

Tuberous Sclerosis Complex (TSC)
Focal Cortical Dysplasia (FCD) Type II

Planned Global Phase 3 Trial

A pivotal global Phase 3 clinical trial is scheduled to launch in Q3 2025, focusing on:

Seizure reduction
Behavioral abnormalities
Functional improvements in GRIN-NDD patients

Terms of the Agreement

GRIN Therapeutics retains exclusive rights in the U.S., Canada, and Mexico
Angelini Pharma gains exclusive commercial rights for the rest of the world

Financial Terms

GRIN receives an upfront payment of $50 million
Clinical development costs will be shared
GRIN is eligible for up to $520 million in milestone payments
GRIN will also receive tiered royalties on global sales and payments from any future sublicense transactions outside Europe

Strategic Vision and Future Outlook

“This partnership with Angelini shows how global collaborations are key to advancing Neurvati’s strategy. “We’re also excited to welcome Jacopo Andreose to our board, bringing global development and commercialization expertise as we head toward Phase 3.”

Dr. Leuchter, President & CEO of GRIN Therapeutics.

Company Profiles

GRIN Therapeutics

Focused on precision therapeutics for pediatric neurodevelopmental disorders, GRIN Therapeutics aims to bring transformative treatments to patients and caregivers with urgent unmet needs.

Neurvati Neurosciences

A Blackstone Life Sciences portfolio company, Neurvati identifies and advances promising neuroscience assets through focused mid-to-late stage development.

Angelini Pharma

An international pharmaceutical company within Angelini Industries, Angelini Pharma has a strong presence in neurology and psychiatry with a commitment to brain health innovation.

Angelini Industries

Founded in 1919 in Ancona, Angelini Industries is a multinational industrial group operating across pharmaceuticals, consumer goods, machinery, and perfumery.

Blackstone Life Sciences

A leading private investment platform, Blackstone Life Sciences invests across all stages of company and product lifecycles within key life science sectors